BIOTECHNOLOGY

Discover how the Luxembourg Institute of Health propels CY-101 toward clinical success in cancer treatment advancements.

Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, today announced the launch of the Cyto-Cellect® Human IgG

This achievement places RenyMed in the top 5% of all companies assessed globally, underscoring its dedication to ethical business practices, environmental stewardship, and workforce well-being.

Guido Baechler, CEO of Mainz Biomed: “Securing the exclusive rights to license this portfolio of novel biomarkers is a major milestone and extension of our previously announced PancAlert program. It provides us with an extraordinary opportunity in the early detection and diagnosis of one of the most challenging cancers to treat. We believe that this achievement marks a paradigm shift in how we can detect pancreatic cancer.”

“This innovative approach supports our strategy to apply Medigene’s 3S TCRs into new TCR-guided modalities, such as TCR-TCEs and now TCR-NKs, to create additional value for both patients and our shareholders,” said Selwyn Ho, CEO of Medigene. “Expanding our TCR-guided therapies to include NK cells aligns with our commitment to developing off-the-shelf, highly specific, and effective immunotherapies for cancer treatment.”